Densitas, MaxQ AI solutions coming to Nuance AI Marketplace

Two healthcare companies focused on AI-powered technologies—Densitas and MaxQ AI—have announced that they will have FDA-approved solutions available on the Nuance AI Marketplace. The marketplace is designed like an app store, giving users of Nuance’s PowerScribe reporting system access to a number of products from different vendors.

Densitas, a breast health company based out of Halifax, Nova Scotia, Canada, is making its densitas densityai breast density assessment software available. The software uses AI to produce reproducible assessments that follow the American College of Radiology’s BI-RADS grading system.

“Our presence on the Nuance AI Marketplace makes us readily accessible to over 6,500 connected healthcare facilities,” Mo Abdolell, CEO of Densitas, said in a prepared statement. “We are excited to see this unique level of workflow integration that supports improved decision making for better patient care and increased reporting efficiency.”

MaxQ AI, meanwhile, is making its ACCIPIO Ix and ACCIPIO Ax platforms available through the marketplace. Both platforms use deep learning algorithms to evaluate imaging findings and help physicians prioritize patients as needed.  

“The Nuance AI Marketplace for Diagnostic Imaging brings our revolutionary AI-powered ICH detection solutions to radiologists across the globe in their preferred workflow,” Gene Saragnese, CEO of MaxQ AI, said in a separate prepared statement. “This availability of our Accipio ICH detection, stroke, and head trauma solutions through Nuance’s cloud-based marketplace will support potential diagnostic improvements, which will improve patient outcomes and lower healthcare costs.”

More information on the Nuance AI marketplace is available here.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.